Gianluca Carloni

Gianluca Carloni

Auto-generated profile, based on publicly available information

Gianluca Carloni

National Research Council Institute of Information Science and Technologies (ISTI) "Alessandro Faedo" Via Moruzzi 1 56127 Pisa Italy IT

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in WIREs Data Mining and Knowledge Discovery
Verified
Journal Article
Open access
GCGianluca Carloni
Gianluca Carloni
ABAndrea Berti
Andrea Berti
SCSara Colantonio
Sara Colantonio
Causality and eXplainable Artificial Intelligence (XAI) have developed as separate fields in computer science, even though the underlying concepts of causation and explanation share common ancient roots. This is further enforced by the lack of review works jointly covering these two fields. In this paper, we investigate the literature to try to understand how and to what extent causality and XAI are intertwined. More precisely, we seek to uncover what kinds of relationships exist between the two concepts and how one can benefit from them, for instance, in building trust in AI systems. As a result, three main perspectives are identified. In the first one, the lack of causality is seen as one of the major limitations of current AI and XAI approaches, and the “optimal” form of explanations is investigated. The second is a pragmatic perspective and considers XAI as a tool to foster scientific exploration for causal inquiry, via the identification of pursue‐worthy experimental manipulations. Finally, the third perspective supports the idea that causality is propaedeutic to XAI in three possible manners: exploiting concepts borrowed from causality to support or improve XAI, utilizing counterfactuals for explainability, and considering accessing a causal model as explaining itself. To complement our analysis, we also provide relevant software solutions used to automate causal tasks. We believe our work provides a unified view of the two fields of causality and XAI by highlighting potential domain bridges and uncovering possible limitations.


15 February 2024 in Expert Systems with Applications
Verified
Journal Article
Open access
GCGianluca Carloni
Gianluca Carloni
SCSara Colantonio
Sara Colantonio

24 November 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
GCGianluca Carloni
Gianluca Carloni
CGCristina Garibaldi
Cristina Garibaldi
GMGiulia Marvaso
Giulia Marvaso
SVStefania Volpe
Stefania Volpe
MZMattia Zaffaroni
Mattia Zaffaroni
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa

6 July 2026 in ESMO Open
Verified
Journal Article
Open access
HKH.-D. Kim
H.-D. Kim
SSS. Shin
S. Shin
WHW. Hwang
W. Hwang
JSJ. Shin
J. Shin
TLTaebum Lee
Taebum Lee
MRM.-H. Ryu
M.-H. Ryu
First-line treatment of gastric cancer is evolving with the integration of immune checkpoint inhibitors (ICIs) and targeted agents, complicating biomarker stratification. Claudin 18.2 (CLDN18.2) is an established target for zolbetuximab; however, immunohistochemistry (IHC) is limited by tissue requirements, cost, and turnaround time. Artificial intelligence (AI) analysis of hematoxylin and eosin (H&E)-stained slides may provide a scalable alternative. We developed and validated an AI model to predict CLDN18.2 expression from H&E slides and evaluated its clinical utility integrated with AI-derived immune phenotyping. This retrospective study included three independent cohorts of patients with gastric cancer. The development cohort comprised 622 patients (497 for training and 125 for tuning). The internal validation cohort included 378 patients treated with first-line nivolumab plus chemotherapy or chemotherapy alone. The external validation cohort included 98 patients from diverse ethnic backgrounds. Whole-slide H&E-stained images were analyzed using a Vision Transformer-based AI model to predict CLDN18.2 expression. A separate AI model classified the immune microenvironment as inflamed or noninflamed. Primary outcomes were predictive performance metrics, including area under the receiver operating characteristic curve (AUROC). Secondary outcomes included progression-free survival (PFS) and overall survival (OS), stratified by AI-predicted CLDN18.2 status and immune phenotype. CLDN18.2 positivity by IHC was 42.9% (development), 36.8% (internal validation), and 25.5% (external validation). The AI model yielded AUROC values of 0.752 (internal validation) and 0.856 (external validation). In the internal validation cohort, patients with AI-predicted CLDN18.2-negative/inflamed tumors exhibited improved outcomes with nivolumab plus chemotherapy versus chemotherapy alone [PFS: hazard ratio (HR) 0.35, 95% confidence interval (CI) 0.15-0.82; OS: HR 0.40, 95% CI 0.18-0.89]. Patients with CLDN18.2-positive/noninflamed tumors showed no benefit from nivolumab plus chemotherapy. An AI model using routine histology predicted CLDN18.2 expression and immune phenotype in gastric cancer, identifying subgroups with differential benefit from ICI-based chemotherapy.